Stockreport

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF - FDA approval based on MARCH Phase 3 study with highly statistically significant (p- Label covers broad range of PFIC subtypes- Immediate launch and availability for el [Read more]